Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) released its earnings results on Friday. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.40), Briefing.com reports. During the same quarter last year, the company earned ($1.85) EPS.
Zentalis Pharmaceuticals Trading Down 9.4 %
Shares of ZNTL opened at $3.00 on Friday. The firm’s fifty day simple moving average is $5.39 and its two-hundred day simple moving average is $10.38. Zentalis Pharmaceuticals has a 12 month low of $2.96 and a 12 month high of $29.03. The stock has a market capitalization of $213.08 million, a P/E ratio of -0.90 and a beta of 1.70.
Insider Buying and Selling
In other news, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on ZNTL
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
- Five stocks we like better than Zentalis Pharmaceuticals
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Best Stocks Under $10.00
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- What is the Australian Securities Exchange (ASX)
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.